Skip to main content
L

Not yet reviewed: this article is pending editorial review by Lyrea.

Citation noticeOur citation system is being overhauled

References and citation markers may currently be incomplete, mismatched, or incorrect. This system is being rebuilt and reviewed before the full site launch.

LSM-775

LSM-775 molecule structureLSM-775 molecule structure
Lysergic acid morpholide
LSM, LA-Morph, Morpholine lysergamide, N-MorpholinyllysergamideOpen in Piru
Psychoactive Class
Chemical Class

LSM-775 is a synthetic psychedelic of the lysergamide class and a close structural relative of LSD.1 In preliminary clinical trials, LSM-775 produced a weak psychedelic response similar to low or threshold doses of LSD2, alongside reportedly dream-like sedation. Albert Hofmann and colleagues described it in the scientific literature by 1955.2 Nausea is a commonly reported adverse effect and can be pronounced.

Dosage & Duration

Dosage

Doses are population estimates that vary widely between individuals.

Threshold250 µg
Light500-750 µg
Moderate750-1250 µg
Strong1250-1500 µg
Heavy1500+ µg

Duration

Onset25-45 minutes
After Effects1-16 hours
Total8-13 hours

Subjective Effects

Subjective Effects not written up yet

Pharmacology

Pharmacodynamics

LSM-775 is a potent full agonist at serotonin 5-HT1A receptors2 and a potent partial agonist at 5-HT2A, 5-HT2B, and 5-HT2C receptors. In rodents, it does not produce the head-twitch response, a behavioral marker of psychedelic-like activity. Findings in this model indicate that its 5-HT1A receptor activation suppresses its psychedelic-like effects.2

Pharmacokinetics

Absorption & half-lifenot documented yetMetabolitesnone documented yet

Interactions

Dangerous

Highest risk

These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.

Unsafe

Avoid

There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.

Caution

Use caution

These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.

Powered by TripSit

Tolerance

Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.

Full Tolerance
Tolerance to LSM-775's effects develops almost immediately following ingestion.
Baseline Reset
Tolerance returns to baseline after approximately 14 days without further LSM-775 use.
Half Tolerance
Tolerance falls to approximately half its initial level within 5–7 days, provided no further LSM-775 is consumed.
Cross Tolerance

Likely cross-tolerance with all psychedelics

Harm Potential

Addiction & Dependence

Psychological

Extremely Low

LSM-775 is not expected to be habit-forming, and repeated administration may reduce the urge to take it again. Like many psychedelics, it likely has an inherent self-limiting pattern of use.

Toxicity

Lethal Dosage

The precise toxic dose is not known. Scientific studies have not evaluated recreational LSM-775 toxicity or its long-term health effects.

Cardiovascular

Compared with LSD, LSM-775 shows less evidence of cardiovascular stimulation and peripheral toxicity; intoxication may still involve hypotension, hypertension, or tachycardia.

Gastrointestinal

Nausea is a common adverse effect and may be intense enough to make the experience much less pleasant; vomiting can also occur.

Psychosis Risk

Low

As with other psychedelics, there is potential for adverse psychological reactions including anxiety, paranoia, and panic attacks, though anxiety may be less common than with other psychedelics. Psychosis risk may be elevated in susceptible individuals or when combined with other substances.

Seizure Risk

Low

Seizure risk is inferred from LSD-associated reports. The main concern appears to be for people with genetic susceptibility, especially when stressors such as dehydration, fatigue, or undernourishment are present.

History & Culture

LSM-775 was first described in the scientific literature by Albert Hofmann and colleagues by 1955.2 A paper examining its activity in animals was published in 1957. Alexander Shulgin later included a brief account of the compound in his 1997 book TiHKAL (Tryptamines I Have…

Legality

By Country

Illegal1
Germany flagGermanyIllegal (analog/blanket ban)
Legal / decriminalized1
United States flagUnited StatesUncontrolled
Not scheduled1
Switzerland flagSwitzerlandNot scheduled

References

Source Pages

  1. Bluelight: The Big & Dandy LSM-775 Thread
  2. Erowid Experience Vaults: LSM-775
  3. Isomer Design (TiHKAL/PiHKAL)
  4. Isomer Design: LSM-775
  5. PsychonautWiki
  6. Shulgin: TiHKAL - LSD-25 Entry
  7. The Drug Classroom
  8. TripSit Factsheets
  9. Wikipedia

Citations

  1. TiHKAL: The Continuation, entry 26: LSD-25. Erowid (1997). https://www.erowid.org/library/books_online/tihkal/tihkal26.shtml1
  2. Return of the lysergamides. Part IV: Analytical and pharmacological characterization of lysergic acid morpholide (LSM-775). Drug Testing and Analysis / LJMU Research Online (2018). https://doi.org/10.1002/dta.222212345678910
  3. TiHKAL, Chapter 26: LSD-25. Erowid (1997). https://erowid.org/library/books_online/tihkal/tihkal26.shtml1
  4. Verordnung der Bundesregierung: Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes. bundesgesundheitsministerium.de (n.d.). https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/N/NpSG_BtMG_VO_AEnd_Anlagen.pdf1
  5. Bundesgesetzblatt 2019 Teil I Nr. 27: Verordnung zur Änderung der Anlage des Neue-psychoaktive-Stoffe-Gesetzes und von Anlagen des Betäubungsmittelgesetzes. bundesgesundheitsministerium.de (n.d.). https://www.bundesgesundheitsministerium.de/fileadmin/Dateien/3_Downloads/Gesetze_und_Verordnungen/GuV/N/NPS_BtM_RegV_Bgbl.pdf1
  6. Neue-psychoaktive-Stoffe-Gesetz (NpSG), Anlage 1. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/anlage_1.html1
  7. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 2 Begriffsbestimmungen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__2.html1
  8. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 3 Unerlaubter Umgang mit neuen psychoaktiven Stoffen. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__3.html1
  9. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 4 Strafvorschriften. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__4.html1
  10. Neue-psychoaktive-Stoffe-Gesetz (NpSG), § 1 Anwendungsbereich. gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/npsg/__1.html1

Further Reading

  1. Gogerty & Dille (1957): Pharmacology of d-LSM
  2. Wagmann et al. 2019 - In vitro metabolic fate of nine LSD-based new psychoactive substances and their analytical detectability in different urinary screening procedures

Article Status

  • Josie Kins avatar
    Step 1 · Automated synthesis

    An autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.

  • Step 2 · First-pass reviewPending

    Not yet reviewed: this article is pending editorial review by Lyrea.

  • Step 3 · Citation reviewPending

    No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.

Suggest an edit

Spotted a mistake, an outdated claim, or something missing from the LSM-775 article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.

Wish to give generalised feedback? You can do so here.